Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 1995;25:694-698

This Article
Right arrow Full Text
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Miao, Z.-H.
Right arrow Articles by Chang, C.-H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Miao, Z.-H.
Right arrow Articles by Chang, C.-H.
Right arrowPubmed/NCBI databases
*Protein
*Compound via MeSH
*Substance via MeSH

(Hypertension. 1995;25:694-698.)
© 1995 American Heart Association, Inc.


Articles

Mutational Inactivation of the Catalytic Domain of Guanylate Cyclase-A Receptor

Zhen-Hua Miao; Dong-Li Song; Janice G. Douglas; Chung-Ho Chang

From the Departments of Medicine and Physiology and Biophysics, Case Western Reserve University, Cleveland, Ohio; and the Department of Medical Genetics, University of Toronto, Ontario, Canada (D.-L.S.).

Correspondence to Dr Chung-Ho Chang, Department of Medicine, Division of Hypertension, Case Western Reserve University School of Medicine, W 165, Cleveland, OH 44106.

Abstract Guanylate cyclase-A, the receptor for atrial natriuretic factor, contains a protein kinase–like domain and a catalytic domain in the intracellular region. To investigate the active site (the catalytic cavity) of guanylate cyclase-A, we amplified the catalytic domain plus three amino acids from the kinase-like domain of guanylate cyclase-A (GC-c) with polymerase chain reaction (PCR) and expressed it in Escherichia coli. During the screening of the PCR-cloned gene products with guanylate cyclase assay, a mutant that lacks enzyme activity was identified. Results of cDNA sequencing revealed that Leu 817 was replaced by an Arg residue in the mutated protein. The mutated GC-c bound to GTP-agarose as well as the wild-type protein, indicating that the binding capability of mutated GC-c to GTP is not significantly affected by the Arg substitution. Gel-filtration column chromatography showed that, like the wild-type GC-c, the mutated protein also formed a high-molecular-weight complex. Since mutation of Leu 817 to Arg abolishes the catalytic activity, Leu 817 is likely located near the active site of guanylate cyclase-A. These results demonstrate that the carboxyl fragment of guanylate cyclase-A is an ideal system for studying the active site of guanylate cyclase-A.


Key Words: guanylate cyclase • mutation • receptors, atrial natriuretic factor




This article has been cited by other articles:


Home page
HypertensionHome page
Z.-J. Chen, M. Vetter, G.-D. Chang, S. Liu, D. Che, Y. Ding, S. S. Kim, and C.-H. Chang
Cyclophilin A Functions as an Endogenous Inhibitor for Membrane-Bound Guanylate Cyclase-A
Hypertension, December 1, 2004; 44(6): 963 - 968.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
M. Vetter, Z.-J. Chen, G.-D. Chang, D. Che, S. Liu, and C.-H. Chang
Cyclosporin A Disrupts Bradykinin Signaling Through Superoxide
Hypertension, May 1, 2003; 41(5): 1136 - 1142.
[Abstract] [Full Text] [PDF]